{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:06:22Z","timestamp":1761059182370},"reference-count":16,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,3,22]],"date-time":"2011-03-22T00:00:00Z","timestamp":1300752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatology Research"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:p><jats:bold>Aim:\u2002<\/jats:bold> We conducted a multicenter trial to evaluate the efficacy and safety of i.v. doripenem (DRPM), a new class of carbapenem, in patients with moderate to severe biliary tract infection based on severity assessment using the Guidelines for the Management of Acute Cholangitis and Cholecystitis (1st Edition).<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> One hundred and nineteen patients with moderate to severe acute cholangitis and\/or cholecystitis were subjected to this study. After the initial collection of bile, patients were administrated DRPM 0.5\u2003g three times daily by i.v. drip infusion.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> The characteristics of the 119 patients were well balanced, including 60 with cholangitis, 44 with cholecystitis and 15 with cholangitis complicated by cholecystitis; there were 88.2% (105\/119) moderate cases and 11.8% (14\/119) severe. Based upon the assumption of the use of bile drainage, the rate of response to DRPM was 92.4% (110\/119) in the group of all patients. The clinical response rates were 95.0% (57\/60) for cholangitis, 93.2% (41\/44) for cholecystitis and 80% (12\/15) for cholangitis complicated by cholecystitis. Also, the clinical response rate was 80% (8\/10) in 10 patients without drainage. In contrast, bacteriological efficacy was assessed in 50 patients, and the response rates were 87.0% (20\/23) in patients with cholangitis, 100% (20\/20) in patients with cholecystitis and 85.7% (6\/7) in patients with cholangitis complicated by cholecystitis. Adverse events were found in six patients (5.0%), but were not serious and disappeared after treatment.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> These findings suggest that DPRM is useful as a new option for moderate to severe biliary tract infection.<\/jats:p>","DOI":"10.1111\/j.1872-034x.2011.00783.x","type":"journal-article","created":{"date-parts":[[2011,3,22]],"date-time":"2011-03-22T23:58:46Z","timestamp":1300838326000},"page":"340-349","source":"Crossref","is-referenced-by-count":4,"title":["Clinical efficacy of i.v. doripenem, a new class of carbapenem, in patients with biliary tract infection: A multicenter trial"],"prefix":"10.1111","volume":"41","author":[{"given":"Susumu","family":"Tazuma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Inui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Tsuyuguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shomei","family":"Ryozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"and the BTI Therapy Research Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,3,22]]},"reference":[{"volume-title":"Guidelines for the Management of Acute Cholangitis\/Cholecystitis","year":"2005","author":"Committee on guidelines for the management of acute cholangitis","key":"e_1_2_6_2_2"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00534-006-1150-0"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2004.11.007"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01083-07"},{"key":"e_1_2_6_6_2","first-page":"781","article-title":"Clinical experience of injectable ciprofloxacin (CIP) for biliary tract infection","volume":"24","author":"Tazuma S","year":"2003","journal-title":"J Biliary Tract Pancreas"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-009-0067-1"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868140-00007"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2006.31"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00464-08"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/35.6.855"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1067\/mge.2002.122334"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00534-002-0710-1"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-001-1247-4"},{"key":"e_1_2_6_15_2","first-page":"862","article-title":"Efficacy and safety of sulbactum\/cefoperazone for hepato\u2010biliary infections","volume":"50","author":"Shinagawa N","year":"1997","journal-title":"Jpn J Antibiot"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v10.i15.2281"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2007.064683"}],"container-title":["Hepatology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1872-034X.2011.00783.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1872-034X.2011.00783.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T16:25:39Z","timestamp":1697387139000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1872-034X.2011.00783.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,22]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1111\/j.1872-034X.2011.00783.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1872-034x.2011.00783.x","archive":["Portico"],"relation":{},"ISSN":["1386-6346","1872-034X"],"issn-type":[{"type":"print","value":"1386-6346"},{"type":"electronic","value":"1872-034X"}],"subject":[],"published":{"date-parts":[[2011,3,22]]}}}